An AI-driven reverse‑engineering approach mines existing pharmacology and gene expression data to reveal additional disease targets for a late‑stage metabolic drug.
Key Takeaways
- THPharm already has a drug in late-stage trials
- THPharm , a South Korean biotech focused on metabolic disease, is trying it the other way around
- Start with a drug that already works; let an AI system figure out everything else it might treat